KMC Systems Introduces KMC 360 Program of Contract Design, Manufacture and Maintenance Services
News Jun 12, 2009
Elbit Systems of America’s KMC Systems introduces KMC 360, the company’s complete program for contract design, manufacture and maintenance. The program is designed to support OEMs and start-ups throughout the entire medical device and instrumentation product lifecycle by centralizing all outsourcing support.
The company’s process streamlines communication, strengthens product quality and results in time-to-market advantages.
“Relying on multiple partners throughout a product’s lifecycle can result in market launch delays, increased costs and inefficiencies,” said Patrick W. McNallen, President, KMC Systems. “Just as a circle is all encompassing, so too is KMC Systems’ portfolio of services. Our customers work with one partner that has the relevant experience and skill set to develop, produce and maintain complex medical devices and instrumentation.”
KMC 360 helps medical companies bring quality products to market on time and on budget as well as reduce manufacturing and field service costs, which is especially critical in times of economic difficulty. The company’s approach is based on defined and proven processes, continual communication and cross-functional collaboration throughout each of the product lifecycle stages.
By allowing companies to work with one experienced partner, KMC 360 smoothes product transitions from design to manufacture, avoiding costly redesigns and delays. It also enhances field maintenance support by allowing end users to leverage KMC Systems’ intimate design knowledge of their systems gained through the design and manufacturing stages.
KMC Systems’ integrated process is ideal for in-vitro diagnostic, surgical, therapeutic and lab automation applications. The company utilizes its multidisciplinary expertise and 30 years of experience to produce and maintain high-quality, complex medical systems such as clinical chemistry analyzers, surgical irrigation pumps, hemodialysis instruments and therapeutic cell processors.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE